Abstract
Well over 200 pyrrolizidine alkaloids are known, distributed in a number of plant families (Huxtable, 1989; Mattocks, 1986). Important pyrrolizidine-containing families include Crotalaria, Symphytum, Heliotropium and Senecio. Alkaloids containing a 1,2-double bond (Fig. 1) are hepatotoxic, producing veno-occlusive disease in experimental animals, livestock and humans. A relatively small number of alkaloids are also pneumotoxic, producing pulmonary arterial hypertension, arterial medial hyperplasia, endothelial proliferation, and right ventricular hypertrophy in selected species (Huxtable, 1990). Pneumotoxic alkaloids include the Crotalaria lkaloids, monocrotaline and fulvine, and the Senecio alkaloids, senecionine and seneciphylline. Pulmonary hyperplasia and right ventricular hypertrophy are produced in rats by monocrotaline following a single injection of 0.12–0.36 mmole/kg, or a total dose of 0.04 mmole/kg given subacutely (Shubat, Hubbard and Huxtable, 1989). However, pneumotoxicity is delayed in appearance. Following a single injection, pulmonary hyperplasia is first detectable after seven days, pulmonary arterial blood pressure is raised after nine days, and right ventricular hypertrophy develops after fourteen days. These effects are caused by hepatic metabolites of monocrotaline. Monocrotaline itself has no effect on the isolated, perfused lung, and lung tissue appears to be incapable of metabolizing the alkaloid (Gillis, Huxtable and Roth, 1978).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Bakke, J. and Gustafsson, J.-A. (1984). Mercapturic acid pathway metabolites of xenobiotics: generation of potentially toxic metabolites during enterohepatic circulation. TIPS 5, 517–521.
Bruner, L.H., Hilliker, K.S. and Roth, R.A. (1983). Pulmonary hypertension and ECG changes from monocrotaline pyrrole in the rat. Am. J. Physiol. 245, H300 - H306.
Dekant, W., Lash, L.H. and Anders, M.W. (1988). Fate of glutathione conjugates and bioactivation of cysteine S-conjugates by cysteine conjugate beta-lyase. In Glutathione conjugation: Mechanisms and Biological Significance, edited by Sies, H. and Ketterer, B. pp. 415–447. Academic Press Limited, London.
Gillis, C.N., Huxtable, R.J. and Roth, R.A. (1978). Effect of monocrotaline pretreatment of rats on removal of 5-hydroxytryptamine and norepinephrine by perfused lung. Brit. J. Pharmacol. 63, 435–443.
Hsu, I.C., Allen, J.R. and Chesney, C.F. (1973). Identification and toxicological effects of dehydroretronecine, a metabolite of monocrotaline. Proc. Soc. Exp. Biol. Med. 144, 834–838.
Huxtable, R.J. (1989). Human health implications of pyrrolizidine alkaloids and herbs containing them. In Toxicants of Plant Origin, Vol I: Alkaloids edited by Cheeke, P.R. pp. 41–86. CRC Press, Boca Raton, FL.
Huxtable, R.J. (1990). Activation and pulmonary toxicity of pyrrolizidine alkaloids. Pharmacology and Therapeutics,in press.
Huxtable, R.J., Ciaramitaro, D. and Eisenstein, D. (1978). The effect of a pyrrolizidine alkaloid, monocrotaline, and a pyrrole, dehydroretronecine, on the biochemical functions of the pulmonary endothelium. Mol. Pharmacol. 14, 1189–1203.
Kedzierski, B. and Buhler, D.R. (1986). The formation of 6,7-dihydro-7-hydroxy-lhydroxymethyl-5H-pyrrolizine, a metabolite of pyrrolizidine alkalods. ChemBiol. Inter. 57, 217–222.
Lafranconi, W.M. and Huxtable, R.J. (1984). Hepatic metabolism and pulmonary toxicity of monocrotaline using isolated perfused liver and lung. Biochem. Pharm. 33, 2479–2484.
Lafranconi, W.M., Ohkuma, S. and Huxtable, R.J. (1985). Biliary excretion of novel pneumotoxic metabolites of the pyrrolizidine alkaloid, monocrotaline. Toxicon 23, 983–992.
Mattocks, A.R. (1968). Toxicity of pyrrolizidine alkaloids. Nature (London) 217, 723–728.
Mattocks, A.R. (1972). Acute hepatotoxicity and pyrrolic metabolites in rats dosed with pyrrolizidine alkaloids. Chem. -Biol. Interactions 5, 227–242.
Mattocks, A.R. (1986). Chemistry and Toxicology of Pyrrolizidine Alkaloids, London: Academic Press, pp. 1–393.
Mattocks, A.R. (1990). Pyrrolizidine alkaloids: what metabolites are responsible for extrahepatic tissue damage in animals? Proceedings of the Third International Symposium on Poisonous Plants, edited by James, L.F., in press.
Mattocks, A.R., Jukes, R. and Brown, J. (1989). Simple procedures for preparing putative toxic metabolites of pyrrolizidine alkaloids. Toxicon 27, 561–567.
Ramsdell, H.S., Kedzierski, B. and Buhler, D.R. (1987). Microsomal metabolism of pyrrolizidine alkaloids from Senecio jacobaea: isolation and quantification of 6,7dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine and N-oxides by high performance liquid chromatography. Drug Metab. Dispos. 15, 32–36.
Roth, R.A., Dotzlaf, L.A., Baranyi, B., Kuo, C.H. and Hook, J.B. (1981). Effect of monocrotaline ingestion on liver, kidney, and lung of rats. Toxicol. Appl. Pharmacol. 60, 193–203.
Shubat, P.J., Hubbard, A.K. and Huxtable, R.J. (1989). Dose-response relationship in intoxication by the pyrrolizidine alkaloid monocrotaline. J. Toxicol. Environ. Health 28, 445–460.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Plenum Press, New York
About this chapter
Cite this chapter
Huxtable, R.J., Bowers, R., Mattocks, A.R., Michnicka, M. (1991). Sulfur Conjugates as Putative Pneumotoxic Metabolites of the Pyrrolizidine Alkaloid, Monocrotaline. In: Witmer, C.M., Snyder, R.R., Jollow, D.J., Kalf, G.F., Kocsis, J.J., Sipes, I.G. (eds) Biological Reactive Intermediates IV. Advances in Experimental Medicine and Biology, vol 283. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5877-0_76
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5877-0_76
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5879-4
Online ISBN: 978-1-4684-5877-0
eBook Packages: Springer Book Archive